U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C19H19F2N7O
Molecular Weight 399.3973
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of L-838417

SMILES

CN1N=CN=C1COC2=NN3C(C=C2C(C)(C)C)=NN=C3C4=CC(F)=CC=C4F

InChI

InChIKey=BQDUNOMMYOKHEP-UHFFFAOYSA-N
InChI=1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C19H19F2N7O
Molecular Weight 399.3973
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

L-838,417 is a subtype-selective GABAA modulator, acting as a partial agonist at alpha2, alpha3 and alpha5 subtypes and an antagonist at the alpha1 subtype. L-838,417 displays anxiolytic effects in vivo and is used as a tool compound to study roles of GABAA subunits.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
2.25 nM [Ki]
0.67 nM [Ki]
0.67 nM [Ki]
79.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
In the model of anxiety L-838,417 was dissolved in a (2-Hydroxypropyl)-beta-cyclodextrin solution and administered intraperitoneally (i.p.) at a volume of 2 ml/kg to male and female adolescent and adult SD rats. Anxiolytic effect of L-838,417 was demonstrated at doses 1-4 mg/kg.
Route of Administration: Intraperitoneal
In Vitro Use Guide
Electrophysiological experiments on were performed on Ltk- cells expressing human cDNA combinations a1b3g2s, a2b3g2s, a3b3g2s and a5b3g2s. Glass coverslips containing the cells in a monolayer culture were transferred to a chamber on the stage of an inverted microscope. Cells were perfused continuously with a solution containing (in mM): 124 NaCl, 2 KCl, 2 CaCl2, 1 MgCl2, 1.25 KH2PO4, 25 NaHCO3, and 11 d-glucose, pH 7.2, and observed with phase-contrast optics. Patch pipettes were pulled with an approximate tip diameter of 2 μm and a resistance of 4 MΩ with borosilicate glass and were filled with (in mM): 130 CsCl, 10 HEPES, 10 EGTA, and 3 Mg+-ATP, pH-adjusted to 7.3 with CsOH. Cells were patch-clamped in whole-cell mode with a List LM-EPC 7 patch-clamp amplifier. Drug solutions were applied by a double-barreled pipette assembly, which was controlled by a stepping motor attached to a Prior manipulator, enabling rapid equilibration around the cell. Increasing GABA concentrations were applied for 10 sec pulses with a 30 sec interval between applications.
Substance Class Chemical
Record UNII
8CZO0970G3
Record Status Validated (UNII)
Record Version